1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

  • July 2020
  • 111 pages
  • ID: 5952321
  • Format: PDF
  • GlobalData
Up to $8096 off Until Oct 31st 2020

Summary

Table of Contents

Search Inside

Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

Summary
Graft versus host disease (GvHD) is a morbid disease and accounts for the highest cause of non-relapse mortality following allogeneic hematopoietic stem cell transplant (HSCT).Mortality is caused by either extensive tissue damage or uncontrolled opportunistic infection due to the immunosuppressive properties of the current GvHD treatment.

Drug-related toxicity issues also contribute significantly to morbidity and mortality in GvHD.The GvHD market is expected to undergo significant change and growth over the next 10 years across the five growth pharmaceutical markets (5GM; India, China, Australia, South Korea, and Japan) covered in this report.

In this report, the analyst examines the current GvHD treatment and prophylaxis landscape and provides detailed insights into the market dynamics of this newly recognized disorder. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for GvHD, and their sales projections within GvHD over the 2018-2028 forecast period.

The GvHD market is expected to undergo significant change and growth over the next 10 years across the five growth pharmaceutical markets (5GM; India, China, Australia, South Korea, and Japan) covered in this report.In this report, the analyst examines the current GvHD treatment and prophylaxis landscape and provides detailed insights into the market dynamics of this newly recognized disorder.

This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for GvHD, and their sales projections within GvHD over the 2018-2028 forecast period.

Currently, the GvHD prophylaxis and treatment algorithm varies significantly among physicians and institutions, largely due to the current treatment options consisting of mostly off-label therapies.Over the forecast period the analyst expects that treatment options for GvHD patients will be expanded as pipeline products with significant clinical evidence are approved and launched for GvHD prophylaxis and treatment.

The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years, other drivers of growth during this period will include.

Key Questions Answered
- How will the GvHD prophylaxis and treatment landscape in the 5GM (India, China, Australia, South Korea and Japan) change from 2018-2028?
- What GvHD prophylaxis agents and treatments are in clinical development?
- How do the clinical and commercial attributes of GvHD prophylaxis and treatment candidates in development compare with one another, and against treatment options?
- What are the remaining unmet needs in GvHD prevention and treatment?
- What drivers and barriers will affect GvHD sales in the 5GM over the forecast period?

Scope
- Overview of therapies used in GvHD prophylaxis in patients receiving allogenic hematopoietic stem cell transplants, and treatments for acute, chronic and steroid-refractory GvHD.
- Topline GvHD prophylaxis and treatment market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include currently available treatments and prophylaxis products, unmet needs and opportunities, and the drivers and barriers affecting GvHD sales in the 5GM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.
- Analysis of the current and future market competition in the GvHD growth markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the GvHD prophylaxis and treatment in growth market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GvHD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($8995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis - Epidemiology Forecast to 2029

  • $ 3995
  • October 2020
  • 58 pages

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum.The ...

  • United Kingdom
  • Canada
  • Autoimmune Disease
  • Epidemiology
  • Industry analysis
  • Hospital Admission
  • Prescription Drug Sales

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on